VYNE Therapeutics Inc.

VYNE Therapeutics Inc. announced a special cash dividend of an estimated $0.38 per share, totaling approximately $16.5 million. This dividend is in connection with the previously announced merger with Yarrow Bioscience, Inc. The dividend will be payable to stockholders and warrant holders of record as of July 22, 2026, with the payment scheduled for July 23, 2026. The payment is contingent upon the closing of the merger, which is expected around July 24, 2026, pending stockholder approval at a special meeting on July 16, 2026.

VYNE Therapeutics Inc. announced a proposed reverse merger with Yarrow Bioscience, Inc., expected to close in Q3 2026, after which the combined entity will trade as YARW on NASDAQ. Yarrow, founded in 2025, is focused on developing novel therapies for thyroid autoimmune diseases, specifically advancing YB-101, a potential first-in-class anti-TSHR antibody for Graves’ Disease (GD) and Thyroid Eye Disease (TED). The company has secured $200 million in funding, including a pre-closing financing, providing a cash runway into 2028, and has received Fast Track Designation for its GD program.

VYNE Therapeutics Inc. announced a proposed merger with Yarrow Bioscience, Inc., a clinical-stage biotechnology company, expected to close in Q3 2026. This follows a strategic review and the termination of clinical trials for its lead product candidates, VYN202 and repibresib, due to a clinical hold and failure to meet primary endpoints, respectively. For Q1 2026, the company reported a net loss of $3.6 million, a significant improvement from $8.6 million in Q1 2025, largely due to reduced R&D expenses as it winds down operations.